Session Name: Poster Session A: Living Donor Liver Transplantation
Date: Saturday, June 11, 2016
Session Time: 5:30pm-7:30pm
Presentation Time: 5:30pm-7:30pm
Location: Halls C&D
Background Predicting risk for recurrence of hepatocellular carcinoma (HCC) following living donor liver transplantation (LDLT) is clinically important.
Methods We performed a retrospective study for assessment of recurrence in 134 recipient who were diagnosed with HCC and performed LDLT following sequential transarterial chemoembolization (TACE) from January 2002 to March 2015 at a single institute. Treatment response was assessed using modified response evaluation criteria in solid tumors (mRECIST) categories: complete response (CR), partial response (PR),stable disease (SD) and progressive disease (PD).We assigned patients to the responder (RP, n=73) or nonresponder (NR=61) group according to treatment response of TACE.the presence of mortality withRn 30 days after LT. Cox proportional hazard models and Kaplan-Meier analysis were utilized to estimate HCC recurrence.
Results TACE responses were: CR=34.3%, PR=20.1%, SD=17.1% and PD=28.4%.Five-year HCC recurrence rate was 9.3% in patients responding to TACE (CR or PR), versus 40.8%, among patientswho did not respond (SD or PD, P=0.000). In multivariate analysis, independent pre-LT predictors of recurrence were pre-LT above Milan(P=0.002), size of larger explant tumor (P=0.015, >3cm vs.≤3 cm), and presence of vascular invasion (P=0.000).
Conclusions TACE response in terms of mRECIST criteria may predict HCC recurrence. However, This has not been proven at the multivariate analysis unlike beyond Milan criteria and the presence of vascular invasion in the LDLT recipient. Further larger study is needed to justify clinical usefulness of mRECIST response to chemoembolization for recurrence estimation of hepatocellular carcinoma in living donor liver transplantation.
CITATION INFORMATION: Cho C, Kim K, Kim S, Lee J, Lee J, Kim J, Choi G.-S, Kwon C, Joh J.-W, Lee N. Clinical Usefulness of mRECIST Response to Chemoembolization for Recurrence Prediction of Hepatocellular Carcinoma in Living Donor Liver Transplantation. Am J Transplant. 2016;16 (suppl 3).
To cite this abstract in AMA style:Cho C, Kim K, Kim S, Lee J, Lee J, Kim J, Choi G-S, Kwon C, Joh J-W, Lee N. Clinical Usefulness of mRECIST Response to Chemoembolization for Recurrence Prediction of Hepatocellular Carcinoma in Living Donor Liver Transplantation. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/clinical-usefulness-of-mrecist-response-to-chemoembolization-for-recurrence-prediction-of-hepatocellular-carcinoma-in-living-donor-liver-transplantation/. Accessed June 15, 2021.
« Back to 2016 American Transplant Congress